All In Biotech

NDA 218710 · Phathom Pharmaceuticals INC

Voquezna

Vonoprazan Fumarate · Oral

Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 17, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

132

24 Phase 3, 29 recruiting

FAERS reports

8,132

5,240 serious, 1,069 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 17, 2024 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LetterLabelReview
2 products under this application
  • VOQUEZNA · VONOPRAZAN FUMARATE EQ 10MG BASE · TABLET, ORAL · Prescription
  • VOQUEZNA · VONOPRAZAN FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vonoprazan" as an intervention, any sponsor and status, largest first.

All 132 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea526
  • off label use520
  • nausea485
  • drug ineffective457
  • gastrooesophageal reflux disease322
  • malaise317
  • decreased appetite272
  • headache271
  • pyrexia253
  • abdominal pain upper251
  • vomiting242
  • product dose omission issue232

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20111
20141
20152
201617
201741
201890
2019119
2020166
2021426
2022807
2023880
20241,448
20252,182
20261,951

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voquezna (Vonoprazan Fumarate)

2024 spending

$31.3M

Beneficiaries

14,985

37,589 claims

Per beneficiary

$2,085

$20.76 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$46,258
2024$31,250,586

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 229 on PubMed

Sponsor: Phathom Pharmaceuticals INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.